

# **ASIAMEDIC LIMITED**

(Incorporated in the Republic of Singapore)  
(Company Registration No.: 197401556E)  
(the “**Company**” and its subsidiaries, collectively, the “**Group**”)

---

## **PROFIT GUIDANCE FOR THE SIX MONTHS ENDING 30 JUNE 2020**

---

Based on the preliminary review of the latest available financial information of the Group and an assessment of the business conditions, the Board of Directors of the Company (the “Board”) wishes to inform that the Group expects to report a consolidated loss for the six months ending 30 June 2020.

The Group’s businesses in 2020 have so far been impacted upon by COVID-19 as follows:

- Onsite health screening – All screening and related services in schools and the community have been suspended during the circuit breaker period as disclosed in our announcement dated 7 April 2020. Some of the services are resuming in June 2020 while some services have not resumed pending the assessment of the overall situation by the Singapore Health Promotion Board.
- Executive health screening and aesthetics – While the executive health screening and aesthetics businesses were exempted from suspension of activities initially, both businesses were not permitted to operate during the circuit breaker period. We only resumed the provision of limited services during the current Phase 1 of the post-circuit breaker period.
- Imaging and international clinic – Although the businesses were permitted to operate during the circuit breaker period, the number of patients decreased substantially. There has been no pick-up in volume in Phase 1 of the post-circuit breaker period so far.

The Group’s consolidated results for the six months ending 30 June 2020 are expected to be published in August 2020.

Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

### **BY ORDER OF THE BOARD**

**Foo Soon Soo (Ms)**  
**Company Secretary**

17 June 2020

This announcement has been reviewed by the Company’s Sponsor, Xandar Capital Pte Ltd, in compliance with Rule 226 of the Rules of Catalist. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 63194954.